共 237 条
[11]
Gray-Schopfer V(2015)Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 16 375-384
[12]
Wellbrock C(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 30-39
[13]
Marais R(2013)Conceptual and technical challenges in network meta-analysis Ann Intern Med 159 130-137
[14]
Nikolaou VA(2012)Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool Res Synth Methods 3 80-97
[15]
Stratigos AJ(2008)Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 956-964
[16]
Flaherty KT(2012)How to use an article reporting a multiple treatment comparison meta-analysis JAMA 308 1246-1253
[17]
Tsao H(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 343 d5928-365
[18]
Flaherty KT(2015)Ranking treatments in frequentist network meta-analysis works without resampling methods BMC Med Res Methodol 15 58-332
[19]
Hodi FS(2012)Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 358-1876
[20]
Fisher DE(2014)Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 323-1888